The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Analysis of microtubule-associated protein tau glycation in paired helical filaments.
Open accessAbstract
Alzheimer's disease is typified by the characteristic histopathological lesions of neurofibrillar plaques and tangles. The latter are composed of paired helical filaments (PHFs), the major components of which are modified forms of the microtubule-associated protein tau. The exact nature of these modifications remains unknown, although the presence of hyperphosphorylated tau in PHFs argues strongly that phosphorylation is one of the modifications that result in the polymerization of tau into PHFs. However, hyperphosphorylation alone is insufficient to explain the formation of PHFs. In an attempt to characterize other post-translational modifications of PHF-tau, we have analyzed its glycation. A fraction of PHF-tau seems to be glycated in vivo, whereas soluble tau from either Alzheimer's disease or non-demented human brain is not glycated at all. Purified tau from bovine brain can be efficiently glycated in vitro. Tau glycation is accompanied by a decrease in the tau binding to tubulin. These results support the view that glycation may be one of the modifications hampering the binding of tau to tubulin in Alzheimer's disease, thus facilitating tau aggregation into PHFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glycated tau is only detected in PHF-tau isolated from AD brain samples, but not in soluble tau from AD or normal brain samples [177, 179].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [177]
In the citing paper
“Tau is preferentially glycated at Lys residues within the microtubule-binding domain, where advanced glycation end products are generated [177–179].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,218
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Schägger, H., & von Jagow, G. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90587-2 · Cited by 11,420
Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane
Fairbanks, G., Steck, T. L., & Wallach, D. F. H. (1971) · Biochemistry · doi:10.1021/bi00789a030 · Cited by 8,526
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,491
Research works printed but not linked: 3
- Greenberg, 1990, Proc. Natl. Acad. Sci. U. S. A., 87, 5825
- Himmler, 1989, Mol. Cell. Biol., 9, 1389
- Maillard, 1912, C. R. Acad. Sci., 154, 66
Cited by
Sorted by citations
Items 201–300 of 333
Singh, M., & Silakari, O. (2016) · RSC Advances · doi:10.1039/c6ra17678j · Cited by 34
Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link
Smith, M. A. (1996) · Diabetologia · doi:10.1007/bf00403972 · Cited by 34
Nuclear face of Tau: an inside player in neurodegeneration
Younas, N., Saleem, T., Younas, A., & Zerr, I. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01702-x · Cited by 34
“With aging, there is an increase of neuronal vulnerability to oxidative damage, that could modify Tau protein [75, 76] facilitating its aggregation [77, 78].”
BackgroundGlycated proteome: From reaction to intervention
Kulkarni, M. J., Korwar, A. M., Mary, S., Bhonsle, H. S., & Giri, A. P. (2012) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201200101 · Cited by 32
“In neurodegenerative diseases, glycation of tau promotes aggregation of paired helical filaments (PHF) [83].”
Background[11] Advanced glycation end products: Detection and reversal
Al‐Abed, Y., Kapurniotu, A., & Bucala, R. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09013-8 · Cited by 33
Early contribution of oxidative glycation in Alzheimer disease
Smith, M. A., Tabaton, M., & Perry, G. L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13100-1 · Cited by 32
A Novel Perspective on Tau in Alzheimers Disease
Bonda, D., Castellani, R. J., Zhu, X., Nunomura, A., Lee, H., Perry, G. L., & Smith, M. A. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717131 · Cited by 32
Canu, N., & Calissano, P. (2003) · The Cerebellum · doi:10.1080/14734220310004289 · Cited by 32
Abortive oncogeny and cell cycle-mediated events in Alzheimer disease
Raina, A. K., Zhu, X., Monteiro, M. J., Takeda, A., & Smith, M. A. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_20 · Cited by 32
Luna‐Muñoz, J., Charles, R., Claude, M., Flores-Rodríguez, P., Ávila, J., Sergio, R., de la Cruz, F., Mena, R., Meraz‐Ríos, M. A., & Florán, B. (2013) · InTech eBooks · doi:10.5772/54228 · Cited by 43
“Tau is further posttranslationally in AD, with modifications of ubiquitination [11, 12], glycation [13, 14], glycosylation [15], nitration [16], polyamination [17], hyperphosphorylation [18, 19] and proteolysis [7, 20-24].”
BackgroundŽilka, N., Kontseková, E., & Novák, M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15203 · Cited by 33
“…that posttranslational modifications of tau protein, such as truncation [70–72], abnormal hyperphosphorylation [38], glycosylation [92], glycation [57,97], ubiquitination [15], polyamination [89] and nitration [42] can influence its conformational characteristics and thus gain a novel toxic…”
Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology
Kalyaanamoorthy, S., Opare, S. K. A., Xu, X., Ganesan, A., & Rao, P. P. N. (2024) · Current Alzheimer Research · doi:10.2174/0115672050301407240408033046 · Cited by 32
Pharmacological considerations for treating neuroinflammation with curcumin in Alzheimer’s disease
Zhou, X., Venigalla, M., Raju, R., & Münch, G. W. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02480-x · Cited by 34
“Furthermore, tau is cross-linked through the oxidation and glycoxidation and forms insoluble deposits which occupy most of the internal intracellular space of an affected neuron (Ledesma et al. 1994; Thome et al. 1996a; Durany et al. 1999).”
BackgroundDiabetes and Cognitive Dysfunction
Sims‐Robinson, C., Kim, B., & Feldman, E. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00013-6 · Cited by 30
Stühler, K., Pfeiffer, K., Joppich, C., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200600089 · Cited by 29
Irisin injection mimics exercise effects on the brain proteome
Dehghan, F., Zamani, S., Barreiro, C., & Jami, M. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15493 · Cited by 29
“In AD, AGE and MG modify tau and beta-amyloid to protease-resistant protein and cause its aggregation (Ledesma et al., 1994).”
BackgroundGlycation in Huntington’s Disease: A Possible Modifier and Target for Intervention
Brás, I. C., König, A., & Outeiro, T. F. (2019) · Journal of Huntington s Disease · doi:10.3233/jhd-190366 · Cited by 29
Noto, L. D., Deture, M. A., & Purich, D. L. (2005) · Microscopy Research and Technique · doi:10.1002/jemt.20195 · Cited by 28
“, 2002), extensive glycation (Ledesma et al., 1994; Smith et al., 1995), as well as extensive ubiquitination (Manetto et al.”
BackgroundRösner, H., Rebhan, M., Vacun, G., & Vanmechelen, E. (1995) · International Journal of Developmental Neuroscience · doi:10.1016/0736-5748(95)00042-f · Cited by 27
Will antioxidants fulfill their expectations for the treatment of Alzheimer disease?
Rottkamp, C. A., Nunomura, A., Hirai, K., Sayre, L. M., Perry, G. L., & Smith, M. A. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00124-x · Cited by 27
Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers
Russell, C. L., Končarević, S., & Ward, M. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132312 · Cited by 26
“Early in the 1990s, the potential role of glycation in the covalent nature of PHF tau was considered as few believed hyperphosphorylation alone was sufficient to cause PHF tau [75].”
Chemical Synthesis of Peptides Containing Site-Specific Advanced Glycation Endproducts
Kaur, H., Kamalov, M., & Brimble, M. A. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00366 · Cited by 27
A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes
Heininger, K. (1999) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199912)14:8 · Cited by 27
Therapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 26
“…(Morishima-Kawashima et al., 1993), nitration (Horiguchi et al., 2003; Reyes et al., 2012), acetylation (Min et al., 2010) and glycation (Ledesma et al., 1994; Yan et al., 1994); however, the timing and significance of these modifications in pathogenesis is frequently debated (reviewed…”
BackgroundSharma, P., & Singh, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121568 · Cited by 25
Potential of a γ-Glutamyl-Transpeptidase-Stable Glutathione Analogue against Amyloid-β Toxicity
More, S. S., & Vince, R. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200113z · Cited by 25
Hernández, F., Pérez, M., Lucas, J. J., & Ávila, J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02455-1 · Cited by 25
Protective effects of vitamin E against hypercholesterolemia-induced age-related diseases
Catalgol, B., & Özer, N. K. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0235-9 · Cited by 24
“The oxidative damage found in Alzheimer’s disease includes advanced glycation end products (Smith et al. 1994; Ledesma et al. 1994), nitration (Good et al.”
BackgroundNanobiotechnology in Neurodegenerative Diseases
Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 22
A Pathophysiological Intersection of Diabetes and Alzheimer’s Disease
Čater, M., & Hölter, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911562 · Cited by 25
“of amyloid-β and tau, resulting in their formation and aggregation [86] (Figure 3).”
BackgroundPreserving Brain Function in Aging: The Anti-glycative Potential of Berry Fruit
Thangthaeng, N., Poulose, S. M., Miller, M. G., & Shukitt‐Hale, B. (2016) · NeuroMolecular Medicine · doi:10.1007/s12017-016-8400-3 · Cited by 22
In vitro tau fibrillization: Mapping protein regions
Santa‐María, I., Pérez, M., Hernández, F., Muñoz, V., Moreno, F. J., & Ávila, J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.06.003 · Cited by 22
The concept of protein folding/unfolding and its impacts on human health
Alaei, L., Ashengroph, M., & Moosavi‐Movahedi, A. A. (2021) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2021.01.007 · Cited by 23
Characterization of the glycated human cerebrospinal fluid proteome
Ramírez-Boo, M., Priego‐Capote, F., Hainard, A., Glück, F., Burkhard, P. R., & Sanchez, J. (2012) · Journal of Proteomics · doi:10.1016/j.jprot.2012.01.017 · Cited by 22
Bhat, W. F., Bhat, S. A., Khaki, P. S. S., & Bano, B. (2014) · Amino Acids · doi:10.1007/s00726-014-1848-2 · Cited by 21
“It is reported that in vitro glycation of tau protein resulted in paired helical filaments (Ledesma et al. 1994).”
BackgroundThe Role of Cardiovascular Risk Factors in Alzheimer's Disease
Ravona‐Springer, R., Davidson, M., & Noy, S. (2003) · CNS Spectrums · doi:10.1017/s109285290001926x · Cited by 20
Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs
Grundman, M., Corey‐Bloom, J., & Thal, L. J. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_23 · Cited by 20
The Rationale for Insulin Therapy in Alzheimer’s Disease
Ribarič, S. (2016) · Molecules · doi:10.3390/molecules21060689 · Cited by 20
“It has been suggested that AGEs’ accelerated the aggregation of both soluble Aβ and tau thus facilitating development of NFTs and amyloid plaques [200,201].”
BackgroundAhmad, S., & Farhan, M. (2016) · Advances in neurobiology · doi:10.1007/978-3-319-28383-8_8 · Cited by 18
Pérez, M., Medina, M., Hernández, F., & Ávila, J. (2018) · BioMolecular Concepts · doi:10.1515/bmc-2018-0001 · Cited by 20
“Tau protein is subject to a wide range of posttranslational modifications, including phosphorylation, isomerization (25, 26), glycation (27, 28), nitration, O-GlcNAc modification, acetylation (29), oxidation (30), crosslinking (31), truncation (32), polyamination, deamination (33), SUMOylation (34), Lysine methylation…”
Backgroundε-Glycation, APP and Aβ in ageing and Alzheimer disease: A hypothesis
Schmitt, H. P. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.016 · Cited by 19
“In vivo, NEG of hyper-phosphorylated s can result in the formation of s AGEs [136,137] that may favour s aggregation into PHF [60] and, like Ab, induce oxidant stress in neurons as well as cytokine release [136,137].”
BackgroundTau Pathology Generated by Overexpression of Tau
Grundke, I., & Iqbal, K. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65494-6 · Cited by 17
Mitochondrial dysfunction in diabetes mellitus
Anderson, C. M. (1999) · Drug Development Research · doi:10.1002/(sici)1098-2299(199901)46:1 · Cited by 18
Manipulation of microglial activity as a therapy for Alzheimer s disease
Ling, E. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s342 · Cited by 15
“Ubiquitinylated tau has been found in the aggregates located in PHF found in AD brain (14), which suggests that the altered tau proteins are attemptedly marked by neurons so that they can be degraded by proteosomes (7).”
BackgroundInfluentialTau as a Molecular Marker of Development, Aging and Neurodegenerative Disorders
Hernández, F., Pérez, M., de Barreda, E. G., Goñi‐Oliver, P., & Ávila, J. (2008) · Current Aging Science · doi:10.2174/1874609810801010056 · Cited by 16
The solution structure of the C-terminal segment of tau protein
Esposito, G., Viglino, P., Novák, M., & Cattaneo, A. (2000) · Journal of Peptide Science · doi:10.1002/1099-1387(200011)6:11 · Cited by 16
Bovine and human tau, highly homologous but less crossreactive: implications for Alzheimer disease
Alonso, A. D. C., Grundke, I., & Iqbal, K. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00051-s · Cited by 16
Glial reaction in aging and Alzheimer's disease
Unger, J. W. (1998) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19981001)43:1 · Cited by 103
Biomarkers of Oxidative Stress in Neurodegenerative Diseases
Rukhsana Sultana, A., Cenini, G., & Butterfield, D. A. (2013) · Wiley eBooks · doi:10.1002/9781118355886.ch14 · Cited by 16
P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro
Sonawane, S. K., & Chinnathambi, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191348 · Cited by 15
“Another important tau PTM is glycation, which reduces tau’s affinity for microtubules [26–28].”
Guan, P.-P., & Wang, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03277-z · Cited by 15
“Tau truncation in AD might later cause glycation [104] and ubiquitination [105].”
BackgroundÁvila, J., de Barreda, E. G., Pallas‐Bazarra, N., & Hernández, F. (2013) · Europe PMC (PubMed Central) · doi:10.13039/501100006373 · Cited by 15
Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau
Far�as, G. A., González-Billault, C. E., & Maccioni, R. B. (1997) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006838626730 · Cited by 15
“1 mM GTP, and incubated for 24 or 48 h at 37°C [35].”
MethodEstrés oxidativo, péptido β-amiloide y enfermedad de Alzheimer
Manzano‐León, N., & Mas‐Oliva, J. (2006) · Gaceta Médica de México · Cited by 16
Cytotoxicity of Maillard reaction products determined with a peptide spot library
Muscat, S., Pischetsrieder, M., Maczurek, A. E., Rothemund, S., & Münch, G. W. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800366 · Cited by 15
Smith, M. A., Richey, P. L., Kutty, R. K., et al. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02962147 · Cited by 15
Baldensperger, T., Preissler, M., & Becker, C. F. W. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00221k · Cited by 17
Ellmer, D., Brehs, M., Haj‐Yahya, M., Lashuel, H. A., & Becker, C. F. W. (2018) · Angewandte Chemie · doi:10.1002/ange.201805238 · Cited by 14
Cellular Protection and Therapeutic Potential of Tocotrienols
Catalgol, B., Batırel, S., & Özer, N. K. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796957436 · Cited by 12
Our Working Point of View of Tau Protein
Ávila, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170600 · Cited by 14
“[43], like neurofibrillary tangles, one of the two”
BackgroundTau Protein and Zebrafish Models for Tau-Induced Neurodegeneration
Ding, Y., Lei, L., Lai, C., & Tang, Z. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180917 · Cited by 13
Tau modifiers as therapeutic targets for Alzheimer's disease
Liu, Q., Lee, H., Honda, K., Siedlak, S. L., Harris, P. L. R., Cash, A., Zhu, X., Ávila, J., Nunomura, A., Takeda, A., et al. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.021 · Cited by 14
Evidence against increased glycoxidation in patients with Alzheimer's disease
Seidl, R., Schüller, E., Cairns, N. J., & Lübec, G. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00576-4 · Cited by 13
Glycemia and Levels of Cerebrospinal Fluid Amyloid and Tau in Patients Attending a Memory Clinic
Exalto, L. G., van der Flier, W. M., Scheltens, P., & Biessels, G. J. (2010) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2010.02854.x · Cited by 13
“The glycation of tau enhances the formation of paired helical filaments, the constituents of neurofibrillary tangles.(16) Despite these previous observations, the results of the current study do not support the hypothesis that dysglycemia is linked to cognitive decline through aberrant amyloid and tau metabolism.”
ResultCoexistence of reactive plasticity and neurodegeneration in Alzheimer diseased brains.
Guevara, J., Dilhuydy, H., Espinosa, B., Delacourte, A., Quirion, R., Mena, R., Joanette, Y., Zenteno, E., & Robitaille, Y. (2004) · Histology and Histopathology · doi:10.14670/hh-19.1075 · Cited by 14
Inhibitors of the Maillard Reaction
Colaco, C. A. L. S., & Harrington, C. R. (1996) · CNS Drugs · doi:10.2165/00023210-199606030-00001 · Cited by 11
Piccirillo, S., Preziuso, A., Cerqueni, G., Serfilippi, T., Terenzi, V., Vinciguerra, A., Amoroso, S., Lariccia, V., & Magi, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115869 · Cited by 10
Oxidative Stress in Alzheimer’s Disease
Ceballos-Picot, I. (1997) · Neuroscience intelligence unit · doi:10.1007/978-3-662-22516-5_5 · Cited by 10
Buée, L., & Delacourte, A. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50023-8 · Cited by 8
Role of Glycation in Amyloid: Effect on the Aggregation Process and Cytotoxicity
Iannuzzi, C., Irace, G., & Sirangelo, I. (2016) · InTech eBooks · doi:10.5772/62995 · Cited by 8
Koh, D.-H., Rho, Y.-J., Lee, S. Y., Kim, K., & Ju, Y. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127267 · Cited by 11
“For example, the level of advanced glycation end products (AGEs), which are elevated in patients with diabetes owing to hyperglycemia, is increased in the brain tissues of patients with Alzheimer’s dementia, causing beta-amyloid aggregation or nerve fiber knot formation by promoting glycation of beta-amyloid and tau p…”
BackgroundOxidative Stress and Protein Deposition Diseases
Mazzulli, J. R., Hodara, R., Lind, S., & Ischiropoulos, H. (2007) · Springer eBooks · doi:10.1007/0-387-25919-8_7 · Cited by 9
Atomic Force Microscopy Applied to the Study of Tauopathies
Amorim, M. D. S. D. N., França, Á. R. S., Santos‐Oliveira, R., Sanches, J. R., Melo, T. M., Pinto, B., Barbosa, L. R. S., & Alencar, L. M. R. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00819 · Cited by 7
Characterization of Alzheimer paired helical filaments by electron microscopy
Hernández, F., Engel, T., Gómez‐Ramos, A., Pérez, M., & Ávila, J. (2005) · Microscopy Research and Technique · doi:10.1002/jemt.20194 · Cited by 7
“, 1997), glycation (Ledesma et al., 1994; Yan et al., 1994), and oxidation (Schweers et al.”
BackgroundThe Biology and Pathobiology of Tau Protein
Hall, G. F. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-788-0_15 · Cited by 6
Nonenzymatic Posttranslational Protein Modifications: Mechanism and Associated Disease Pathologies
Khan, S., & Bhat, A. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811913-6.00010-2 · Cited by 6
Serum-dependent and -independent regulation of PARP2
Sun, Q., Gatie, M. I., & Kelly, G. M. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0345 · Cited by 6
Apoptotic and Oxidative Indicators in Alzheimer's Disease
Raina, A. K., Sayre, L. M., Atwood, C., Rottkamp, C. A., Hochman, A., Zhu, X., Obrenovich, M. E., Shimohama, S., Nunomura, A., Takeda, A., et al. (2003) · Humana Press eBooks · doi:10.1385/1-59259-188-4:225 · Cited by 6
Dysfunctional gene splicing in glucose metabolism may contribute to Alzheimer's disease
Deng, S., Peng, Y., Xu, M., Yi, Q., & Feng, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002214 · Cited by 5
Akhter, F., Akhter, A., & Ahmad, S. (2017) · Environmental science and engineering · doi:10.1007/978-3-319-46248-6_5 · Cited by 5
Oxidative Stress in Alzheimer’s Disease: A Critical Appraisal of the Causes and the Consequences
Chang, J., Siedlak, S. L., Moreira, P. I., Nunomura, A., Castellani, R. J., Smith, M. A., Zhu, X., Perry, G. L., & Casadesús, G. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-956-7_9 · Cited by 4
Nuclear microscopy of diffuse plaques in the brains of transgenic mice
Rajendran, R., Ren, M., Casadesús, G., et al. (2005) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/j.nimb.2005.01.078 · Cited by 4
Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease
Zhu, X., Perry, G. L., & Smith, M. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_19 · Cited by 4
Oncogenic parallels in Alzheimer disease
Raina, A. K., Garrett, M. R., Previll, L. A., Obrenovich, M. E., Hartzler, A., Webber, K. M., Casadesús, G., Lee, H., Perry, G. L., Zhu, X., et al. (2006) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 4
Chinnathambi, S. (2024) · Cellular Physiology and Biochemistry · doi:10.33594/000000693 · Cited by 3
Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments
Domene-Serrano, I., Cuadros, R., García‐Escudero, V., Vallejo-Bedia, F., Santa‐María, I., Vallés‐Saiz, L., Hernández, F., & Ávila, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00809 · Cited by 3
Khadgawat, P., Siddesha, J. M., Shashank, D., & Shashanka, K. P. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210018 · Cited by 4
“Tau protein, similar to any other protein, can undergo various post-translational modifications including phosphorylation, acetylation [51], nitration [52], glycation [53], etc.”
BackgroundThe Role of Oxidative Stress in the Pathological Sequelae of Alzheimer Disease
Smith, M. A., & Perry, G. L. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2907-8_19 · Cited by 3
Molecular mimicry and the T-cell repertoire
Baum, H. (1996) · Diabetologia · doi:10.1007/bf00403971 · Cited by 3
Harrington, C. R., & Wischik, C. M. (1995) · International Review of Psychiatry · doi:10.3109/09540269509022988 · Cited by 3
Tau protein aggregation: A therapeutic target for neurodegenerative diseases
Duggal, A., Mahindru, D., Baghel, K., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.11.012 · Cited by 2
Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification
Lovestone, S. (1997) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651509709069201 · Cited by 2
Reactive oxygen and nitrogen species: Weapons of neuronal destruction
Mazzulli, J., Lind, S., & Ischiropoulos, H. (2005) · Cited by 2
Massive glycation of protein HC, a low molecular weight lipocalin, in non‐diabetic individuals
Bonay, P., Solı́s, J., de la Calle, H., Fresno, M., GRUBB, A. O., & Méndez, E. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01220-9 · Cited by 2
Self-citationFISETIN – A PROSPECTIVE NEUROPROTECTIVE AGENT WITH MULTI-MOLECULAR TARGET ‘S: A REVIEWPreprint
Ravula, A. R., Teegala, S. B., Pasangulapati, J. P., Perumal, V., Shanker, K., & Boyina, H. K. (2024) · doi:10.22541/au.170665458.88955468/v1 · Cited by 2
Nutrients and Food Constituents in Cognitive Decline and Neurodegenerative Disease
Joseph, J. A., Casadesús, G., Smith, M. A., Perry, G. L., & Shukitt‐Hale, B. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-391884-0.00020-2 · Cited by 1
The Aetiology of Alzheimer’s Disease: Diverse Routes into a Common Tau Pathway
Harrington, C. R. (2001) · Elsevier eBooks · doi:10.1016/b978-044450811-9/50030-6 · Cited by 1
Contribution of Dietary Carbohydrates in Induction of Oxidative Stress
Farooqui, A. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-04111-7_8 · Cited by 2
Effect of Diabetes on Dementia and Its Preventive Strategies
Kim, S. (2012) · Journal of Korean Diabetes · doi:10.4093/jkd.2012.13.3.140 · Cited by 1
Involvement of Complex Carbohydrate Chemistry in Alzheimer’s Disease
DeWitt, D. A., Castellani, R. J., Perry, G. L., et al. (2005) · Scholars Crossing (Liberty University) · Cited by 1
Metadata
- Authors
- Ledesma, M. D., Bonay, P., Colaço, C., & Avila, J.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- ORCID
- Ledesma, M.D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1994-08
- Volume
- 269
- Issue
- 34
- Pages
- 21614-21619
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1577069180
- Semantic Scholar
- 68928334bcb2a45f531ceaeaa8ef0e1a72308735
- Cited by
- 333
- References
- 72
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 2 · 2019: 12 · 2018: 13 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 13 · 2013: 11 · 2012: 13
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein, glycation, paired helical filaments, Alzheimer's disease, post-translational modification, tau aggregation, neurofibrillary tangles, hyperphosphorylation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Animals, Brain Chemistry, Cattle, Diabetes Mellitus, Humans, Lysine, Microtubules, Molecular Sequence Data, Protein Binding, Neurofibrillary Tangles, tau Proteins, Glycation End Products, Advanced, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
